Background The aim of the study was to assess the effect of chronic cardiac failure (CCF) on circulating plasma concentrations of tumour metabolic marker dimeric pyruvate kinase type M2 (M2-PK).
Introduction
Of recent interest in tumour biology and diagnosis is the use of novel biochemical energy markers. The key regulator of metabolic alterations found in tumour cells is the glycolytic isoenzyme pyruvate kinase type M2 (M2-PK), which is generally expressed in all proliferating cells and is overexpressed in all tumour cells investigated. During carcinogenesis a shift in pyruvate kinase isoenzyme equipment always takes place, such that the tissue-speci¢c isoenzymes (L-type in liver and proximal tubules; R-type in erythrocytes; M1-type in skeletal muscle, heart and brain; M2-type in the lung, distal tubules of the kidneys and fetal and undi¡erentiated or proliferating tissue) disappear and M2-PK is expressed.
Pyruvate kinase type M2 can exist in a highly active tetrameric form with a high a⁄nity for its substrate phosphoenolpyruvate (PEP) and in dimeric form with low PEPa⁄nity. The dimeric form of M2-PK is virtually inactive at cellular PEP concentrations. When M2-PK is dimeric, glucose carbons are channelled to synthetic processes such as nucleic acids, phospholipid and amino acid synthesis. 1 It has been shown for various tumours that tumour M2-PK determination provides a discrimination between benign and malignant disease, response to treatment and disease progression. 1 Tumour M2-PK has also been shown to be elevated in some benign conditions such as diabetic nephropathy 2 and rheumatic diseases, 3 together with some benign in£ammatory conditions. 4 Resting energy expenditure in patients with stable chronic cardiac failure (CCF) has been shown to be elevated, probably related to increased ventilation. 5 Since M2-PK is a marker of metabolic activity, the aim of this investigation was to determine if circulating plasma concentrations of dimeric M2-PK were increased in patients with CCF, which may in£uence the interpretation of results when M2-PK is used as a tumour metabolic marker.
Methods

Subjects
Fifty patients with CCF (35 men, 15 women; median age 71 years, range 42^99 years) were studied. All Short Report patients had a prior history of hospital admission for pulmonary oedema on at least one occasion. All had a cardiothoracic ratio of 40.5 on a plain chest X-ray and all had a left ventricular ejection fraction of 540% on echocardiography. The aetiology of CCF was ischaemia in 40 patients, dilated cardiomyopathy in eight and viral cardiomyopathy in two. Symptom status was graded according to the New York Heart Association (NYHA) classi¢cation: 14 patients were in NYHA grade 2, 26 were in NYHA grade 3 and 10 were in NYHA grade 4. All patients were being treated with standard medical therapy, including a diuretic, an angiotensin-converting enzyme (ACE) inhibitor and a b-adrenergic receptor antagonist. All patients had been clinically stable for at least 3 months prior to study. The only exclusion criterion was a history of past or ongoing malignancy. No subject had a prior history of rheumatic disease or diabetes mellitus.
Controls
The control population consisted of 10 normal, healthy individuals (median age 60.9 years, range 48^67 years) with no cardiac or pulmonary disease. None had a history of diabetes mellitus or rheumatic disease. They were determined to be healthy on the basis of a normal clinical history, examination and exercise test. All were sedentary and taking no medications when blood was collected.
All blood samples used were those collected as part of routine clinical care. EDTA plasma was used for the analysis of M2-PK and stored at 308C prior to analysis.
Analysis of pyruvate kinase type M2
The analysis of immunoreactive M2-PK was performed using an enzyme-linked immunosorbent assay (ELISA) according to manufacturer's instructions (Schebo Biotech, Giesson, Germany). This assay uses monoclonal antibodies against dimeric M2-PK which do not cross-react with the tetrameric form or other PK isoforms. The limit of detection was 5 U/mL of EDTA plasma. The intra-assay coe¡ecient of variation (CV) across the range 10^80 U/mL was, on average, 3.5% (range 2.4^7%). The mean inter-assay CV was 5.3% (range of 3.3^7.5%) (manufacturer's data).
Pyruvate kinase type M2 concentrations have been shown to be a¡ected by haemolysis, icterus and lipaemia; however, the degree of haemolysis, icterus or lipaemia is not stated. 6 All samples included in the study were free from these interferents, as judged by visual inspection.
Ethics
The study was approved by the South Manchester local research ethics committee, and all patients gave informed consent for blood samples, collected as part of routine clinical care, to be used in this study.
Statistics
Non-parametric statistics were used throughout. Comparison of M2-PK with NYHA grade was performed by Kruskal^Wallis test. Correlation of M2-PK with sodium, urea and creatinine was made by Spearman's correlation (rs). A P value of 0.05 was taken as the level of statistical signi¢cance.
Results
The results for dimeric M2-PK are summarized in Table 1 . The M2-PK concentration increased signi¢cantly with increasing clinical severity as assessed by the NYHA grade. No signi¢cant correlation was observed between concentrations of M2-PK and serum sodium (rs ¼ 70.36, P ¼ 0.06), urea (rs ¼ 0.3, P ¼ 0.1) or creatinine (rs ¼ 0.8, P ¼ 0.5).
Discussion
The results of this investigation demonstrate that dimeric M2-PK concentration increased signi¢cantly with increasing clinical severity of CCF.
The physiological signi¢cance of increased M2-PK in CCF remains unclear; however, patients with CCF have a number of metabolic changes. An increased resting energy expenditure, probably related to increased ventilation, 5 and a state of increased neurohormonal activation have been described.
Increased dimeric M2-PK concentration in CCF may relate to the metabolic alterations that occur and may help balance the shift between increased glycolytic £ux whilst maintaining the availability of glycolytic intermediates for synthetic purposes.
Concentrations of M2-PK have been shown to be a¡ected by lipaemia and icterus, but it is di⁄cult to draw any conclusions regarding the clinical signi¢cance of these changes in relation to abnormalities in bilirubin and lipaemia observed in CCF, especially since the concentrations of bilirubin and triglyceride causing analytical interference in M2-PK have not been documented. No signi¢cant correlation was observed between concentrations of M2-PK and serum sodium, urea or creatinine, suggesting that abnormalities in renal function do not account for the increase in M2-PK concentration observed in CCF. Unfortunately, liver function tests were not performed routinely. The result of this investigation also has signi¢cance for the interpretation of M2-PK concentrations in clinical practice, which may be confounded by CCF.
Conclusion
We have demonstrated an increase in dimeric M2-PK concentration in patients with CCF, which may serve to balance the increased glycolytic rate while maintaining a su⁄cient supply of glycolytic intermediates for synthetic processes. The results of this investigation also have signi¢cance for the interpretation of M2-PK concentrations in clinical practice, as we have documented another condition in which M2-PK concentrations are elevated.
